Prescient Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), concentrated on applying man-made brainpower (“AI”) to customized prescription and medication disclosure, today declared that dependent on a notice letter (the “Notice Letter on Compliance”) as of late got from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”), the Company has recovered consistency with the base offer value necessity set out in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Base Bid Price Requirement”).
On November 16, 2018, the Company got a warning letter from the Nasdaq (the “Notice Letter on Deficiency”) demonstrating that the end offer value per share had been underneath $1.00 for a time of 30 Consecutive business days and that the Company didn’t meet the Minimum Price Bid Requirement. As per the Notification Letter on Deficiency, if whenever during the Compliance Period, the end offer cost for the Company is, at any rate, $1.00 for at least 10 successive business days, Nasdaq will give the Company a composed affirmation of consistence and the issue will be shut.
As per the Notification Letter on Compliance, the staff of Nasdaq has confirmed that for the 10 back to back business days, starting from October 29, 2019, to November 11, 2019, the end offer cost Of the Company’s regular stock has been at $1.00 per share or more prominent, and the Company has recovered consistency with the Minimum Bid Price Requirement, and the issue is presently shut.
Prescient Oncology works through five fragments (Domestic, International, Clinical, CRO, and DCHIP), which contain four backups; Skyline Medical, and Skyline Europe. Helomics applies man-made consciousness to its rich information assembled from understanding tumors to both customize malignant growth treatments for patients and drive the improvement of new focused on treatments in joint efforts with pharmaceutical organizations. Helomics’ CLIA-ensured lab gives clinical testing that helps oncologists in individualizing persistent treatment choices, by giving a proof-based guide to treatment. Notwithstanding its restrictive accuracy oncology stage, it offers boutique CRO benefits that influence its TruTumor™, tolerant inferred tumor models coupled to a wide scope of measures (genomics, proteomics and biochemical), and an AI-controlled exclusive bioinformatics stage (D-CHIP) to give a customized answer for its customers’ particular needs.